Onco-Innovations Limited Completes Debt Settlement Through Share Issuance

Calgary, Canada — September 16, 2026 — Leads & Copy — Onco-Innovations Limited has successfully closed a debt settlement valued at $481,694, settling outstanding debts owed to certain insiders and consultants by issuing 860,168 common shares. The shares were issued at a deemed price of $0.56 per share, fulfilling the terms of debt settlement agreements made on August 31, 2026.

The settlement involved issuing shares to RHM Management Inc., an entity controlled by David Antony, the Company's Chief Financial Officer and Corporate Secretary, and Carnarvon Strategies-Health Industry Solutions Inc., controlled by Thomas O’Shaughnessy, the Company’s Chief Executive Officer. These transactions are considered related party transactions under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (MI 61-101).

Onco-Innovations is relying on exemptions from formal valuation and minority approval requirements under MI 61-101, as neither the fair market value of the shares nor the consideration paid exceeded 25% of the Company’s market capitalization. This approach aims to streamline the settlement process while adhering to regulatory guidelines.

Onco-Innovations Limited is a Canadian company focused on cancer research and treatment, with a specialization in oncology. The company's mission centers on advancing cancer prevention and treatment through innovative research and solutions. Onco possesses an exclusive worldwide license for patented technology designed to target solid tumors, positioning the company at the forefront of oncological advancements.

Source: Onco-Innovations Limited